代谢相关脂肪性肝病患者肝组织学表现研究*

doi:10.3969/j.issn.1672-5069.2025.05.018

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (5): 711-714.doi: 10.3969/j.issn.1672-5069.2025.05.018

代谢相关脂肪性肝病患者肝组织学表现研究^*

杨欢, 袁宏伟, 奇丽娜, 陈平

010030 呼和浩特市内蒙古医科大学附属医院(杨欢,陈平,奇丽娜);基础医学院病理学教研室(袁宏伟)

收稿日期:2024-11-22 出版日期:2025-09-10 发布日期:2025-09-19
通讯作者: 陈平,E-mail:nmgcp@sina.com
作者简介:杨欢,女,27岁,硕士研究生,住院医师。主要从事各种慢性肝脏疾病诊治研究。E-mail:920658967@qq.com
基金资助:
*国家自然科学基金资助项目(编号:82260115);内蒙古自治区自然科学基金资助项目(编号:2024LHMS08012);内蒙古医科大学附属医院院级科研项目资助(编号:2023NYFYTS019)

Liver histo-pathological manifestation in patients with metabolic fatty liver disease: An analysis of 35 cases

Yang Huan, Yuan Hongwei, Qi Lina, et al

Department of Gastroenterology, Affiliated Hospital, Inner Mongolia Medical University, Hohhot 010030,Inner Mongolia Autonomous Region, China

Received:2024-11-22 Online:2025-09-10 Published:2025-09-19

摘要/Abstract

摘要： 目的本研究旨在分析代谢相关性脂肪性肝病(MAFLD)患者肝组织病理学表现。方法 2017年8月～2022年12月我院诊治的MAFLD患者35例,均接受肝穿刺检查。结果在本组35例患者中,肝组织病理学检查发现肝脂肪变性0级8例(22.9%),1级16例(45.7%),2级5例(14.3%),3级6例(17.1%),即肝组织细胞脂肪变性27例(77.1%),其中脂肪肝活动指数(NAS)评分≥5分(代谢相关性脂肪性肝炎)者11例(31.4%);肝细胞气球样变26例(74.4%),小叶炎症32例(91.4%),无小叶炎症者3例(8.6%),其中1级14例(40.0%),2级12例(34.3%),3级6例(17.1%);未出现肝细胞气球样变者9例(25.7%);可见马洛里小体(Mallory-body)5例(14.3%);未出现肝纤维化者5例(14.3%),显著性肝纤维化者16例(45.7%),进展性肝纤维化者14例(40.0%)。结论尽早完善肝穿刺活检有助于早期明确MAFLD患者肝组织学病理学变化,从而早诊早治,延缓甚至逆转疾病发展,有较大的临床应用价值。

关键词: 代谢相关脂肪性肝病, 肝穿刺活检, 组织病理学

Abstract: Objective The purpose of this study was to analyze the histo-pathological manifestations of liver biopsy tissues in patients with metabolic-associated fatty liver disease (MAFLD). Methods In this study, a retrospective analysis was performed to collect liver tissue data in 35 patients with MAFLD. All patients underwent liver biopsies in our hospital between August 2017 and December 2022, and the histological manifestations of liver tissues were observed. Results Of the 35 patients with MAFLD, liver histo-pathological examination showed liver steatosis F0 in 8 cases(22.9%), F1 in 16 cases (45.7%), F2 in 5 cases (14.3%) and F3 in 6 cases (17.1%), e.g., liver steatosis in 27 cases (77.1%), of them, the MAFLD activity score (MAS)≥5, suggesting MASH in 11 cases (31.4%); hepatocellular ballooning in 26 cases (74.4%), with and without lobular inflammation in 32 cases (91.4%)and in 3 cases (8.6%), of them, grade 1 in 14 cases (40.0%), grade 2 in 12 cases (34.3%) and grade 3 in 6 cases (17.1%); Mallory-body was found in 5 cases (14.3%); no liver fibrosis in 5 cases (14.3%), significant liver fibrosis in 16 cases (45.7%) and advanced liver fibrosis in 14 cases (40.0%). Conclusion Liver biopsy is important for clarification of histopathological changes, which might help clinicians make an appropriate measures to deal with it.

Key words: Metabolism-related fatty liver disease, Liver biopsy, Histopathology

杨欢, 袁宏伟, 奇丽娜, 陈平. 代谢相关脂肪性肝病患者肝组织学表现研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 711-714.

Yang Huan, Yuan Hongwei, Qi Lina, et al. Liver histo-pathological manifestation in patients with metabolic fatty liver disease: An analysis of 35 cases[J]. Journal of Practical Hepatology, 2025, 28(5): 711-714.

参考文献

[1] Wang XJ, Malhi H. Nonalcoholicfatty liver disease. Ann Intern Med,2018,69(9):65-80.
[2] Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl), 2020,134(1):8-19.
[3] Eslam M,Sanyal AJ,George J.International consensus panel.MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020,158(7):1999-2014.
[4] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020,73(1):202-209.
[5] Alharthi J, Gastaldelli A, Cua IH,et al. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol, 2022,38(3):251-260.
[6] Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol, 2020,17(7):387-388.
[7] Fouad Y, Waked I, Bollipo S, et al. What's in a name? Renaming 'NAFLD' to 'MAFLD'. Liver Int, 2020,40(6):1254-1261.
[8] Nalbantoglu IL, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol, 2014,20(27):9026-9037.
[9] Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol, 1999,94(9):2467-2474.
[10] Kleiner DE, Brunt EM, Van Natta M, et al.Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005,41(6):1313-1321.
[11] Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol, 2010,7(4):195-203.
[12] Tandra S, Yeh MM, Brunt EM, et al. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol, 2011,55(3):654-659.
[13] Germano CW, Mega PF, Mattosinho TJAP,et al. Microvesicular steatosis in individuals with obesity: A histological marker of non-alcoholic fatty liver disease severity. Obes Surg, 2023,33(3):813-820.
[14] Angulo P, Kleiner DE, Dam-Larsen S,et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 2015,149(2):389-397.
[15] Nassir F. NAFLD: Mechanisms, treatments, and biomarkers. Biomolecules, 2022,12(6):824.
[16] Mazzolini G, Sowa JP, Atorrasagasti C, et al. Significance ofsimple steatosis: An update on the clinical and molecular evidence. Cells, 2020,9(11):2458.
[17] Lomonaco R, Godinez Leiva E, Bril F, et al. Advanced liver fibrosis is common in patients with Type 2 Diabetes followed in the outpatient setting: The need for systematic screening. Diabetes Care, 2021,44(2):399-406.
[18] Ampuero J, Aller R, Gallego-Durán R, et al. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. J Hepatol, 2020,73(1):17-25.
[19] Zaharia OP, Strassburger K, Strom A, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol, 2019,7(9):684-694.
[20] Zaharia OP, Strassburger K, Knebel B, et al. Role of patatin-like phospholipase domain-containing 3 gene for hepatic lipid content and insulin resistance in diabetes. Diabetes Care, 2020,43(9):2161-2168.
[21] Dhar D, Baglieri J, Kisseleva T, et al. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood), 2020,245(2):96-108.
[22] Ostovaneh MR, Ambale-Venkatesh B, Fuji T, et al. Association of liver fibrosis with cardiovascular diseases in the general population: The multi-ethnic study of atherosclerosis (MESA). Circ Cardiovasc Imaging,2018,11(3):e007241.

代谢相关脂肪性肝病患者肝组织学表现研究^*

Liver histo-pathological manifestation in patients with metabolic fatty liver disease: An analysis of 35 cases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韩煜东, 张杰, 章文瑾, 何年安. 超声来源的脂肪分数诊断代谢相关脂肪性肝病应用研究[J]. 实用肝脏病杂志, 2025, 28(4): 553-556.
[2]	杨浩, 易波, 刘洪岩. T2DM合并代谢相关脂肪性肝病患者血清IFN-α和IFN-β水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(4): 557-560.
[3]	刘倩, 杨洁, 张静, 宫克, 郭瑞丹. 慢性乙型肝炎合并代谢相关脂肪性肝病患者外周血单个核细胞Galectin-3和Galectin-9水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(3): 338-341.
[4]	卫涛涛, 刘天烨, 戴高中. 代谢相关脂肪性肝病患者回肠菌群特征研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 354-357.
[5]	董旭, 王超群, 陈怡, 朱彤, 葛玲玲, 徐爱静. 估算葡萄糖处置率评估无糖尿病人群代谢相关脂肪性肝病发生风险效能研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 362-365.
[6]	秦浩, 方春华, 何競, 张磊, 冉斌, 汪丽萍, 张振华. 六种无创评分诊断2型糖尿病合并代谢相关脂肪性肝病患者效能比较^*[J]. 实用肝脏病杂志, 2025, 28(3): 366-369.
[7]	朱帝文, 张媛, 鲍应军, 顾俊鹏, 孙丽华, 任伟新. 经颈静脉穿刺肝组织活检操作要点及并发症分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 290-293.
[8]	黄嘉伟, 纪雅丽, 周玲, 陈金军. 代谢相关脂肪性肝病患者SAF评分和脂肪肝进展抑制算法应用研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 48-51.
[9]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[10]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[11]	周丽丽, 施漪雯, 范建高, 孙超. 伴有ABCA1基因突变的青年代谢相关脂肪性肝硬化1例报道[J]. 实用肝脏病杂志, 2024, 27(4): 638-640.
[12]	曹焱芬, 邹昊轩, 谢艳. 体检人群血浆致动脉粥样硬化指数诊断代谢相关脂肪性肝病效能分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 361-365.
[13]	金伯旬, 张丽, 娜仁图雅, 齐丽艳, 边新渠, 刘海霞, 王鑫, 栗光明. 急性表现与非急性表现的自身免疫性肝炎患者临床和肝组织病理学特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 366-369.
[14]	刘恋, 吉飞跃, 陈诺儿. 自身免疫性肝炎患者外周血单个核细胞CD6及其配体激活的白细胞粘附分子水平变化临床价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 370-373.
[15]	贾永利, 王鹏川, 郭伟, 孙东莹. 低频与高频超声联合诊断胆囊息肉样病变价值分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 307-310.